Bioelectronics Corp
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain therapy; Allay, a menstrual pain therapy; and Smart Insole, a heel pain therapy. The company also offers RecoveryRx, a medical device that pro… Read more
Bioelectronics Corp (BIEL) - Total Assets
Latest total assets as of March 2023: $170.37K USD
Based on the latest financial reports, Bioelectronics Corp (BIEL) holds total assets worth $170.37K USD as of March 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bioelectronics Corp - Total Assets Trend (2013–2024)
This chart illustrates how Bioelectronics Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bioelectronics Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Bioelectronics Corp's total assets of $170.37K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.2% |
| Accounts Receivable | $4.20K | 9.7% |
| Inventory | $31.25K | 72.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Bioelectronics Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioelectronics Corp's current assets represent 100.0% of total assets in 2024, an increase from 97.2% in 2013.
- Cash Position: Cash and equivalents constituted 18.2% of total assets in 2024, up from 3.2% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 72.1% of total assets.
Bioelectronics Corp Competitors by Total Assets
Key competitors of Bioelectronics Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cheelcare Inc.
V:CHER
|
Canada | CA$4.27 Million |
|
FluroTech Ltd
OTCQB:FLURF
|
USA | $282.20K |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
Bioelectronics Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Bioelectronics Corp generates 11.45x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Bioelectronics Corp is currently not profitable relative to its asset base.
Bioelectronics Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 0.05 | 0.11 |
| Quick Ratio | 0.02 | 0.04 | 0.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.44 Million | $ -6.48 Million | $ -6.01 Million |
Bioelectronics Corp - Advanced Valuation Insights
This section examines the relationship between Bioelectronics Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -70.0% |
| Total Assets | $43.33K |
| Market Capitalization | $2.97 USD |
Valuation Analysis
Below Book Valuation: The market values Bioelectronics Corp's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bioelectronics Corp's assets decreased by 70.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bioelectronics Corp (2013–2024)
The table below shows the annual total assets of Bioelectronics Corp from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $43.33K | -69.99% |
| 2023-12-31 | $144.39K | -42.29% |
| 2022-12-31 | $250.19K | +198.25% |
| 2021-12-31 | $83.89K | -80.27% |
| 2020-12-31 | $425.17K | +23.28% |
| 2019-12-31 | $344.89K | -26.46% |
| 2018-12-31 | $468.97K | -6.79% |
| 2017-12-31 | $503.11K | -29.50% |
| 2016-12-31 | $713.68K | -28.71% |
| 2015-12-31 | $1.00 Million | +44.53% |
| 2014-12-31 | $692.62K | -22.25% |
| 2013-12-31 | $890.88K | -- |